{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:11:43Z","timestamp":1790799103252,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jbspin.2021.105143","type":"journal-article","created":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T21:34:12Z","timestamp":1611783252000},"page":"105143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?"],"prefix":"10.1016","volume":"88","author":[{"given":"Alina","family":"Dima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Jurcut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-8394","authenticated-orcid":false,"given":"Laurent","family":"Arnaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2021.105143_bib0500","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.semarthrit.2013.01.001","article-title":"Multifaceted effects of hydroxychloroquine in human disease","volume":"43","author":"Olsen","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105143_bib0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2020-4-5","article-title":"Chloroquine and hydroxychloroquine in the context of COVID-19","volume":"9","author":"Shukla","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.jbspin.2021.105143_bib0510","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1136\/annrheumdis-2020-217877","article-title":"EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2","volume":"79","author":"Landew\u00e9","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0515","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/postgradmedj-2020-137785","article-title":"Hydroxychloroquine and COVID-19","volume":"96","author":"Sinha","year":"2020","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jbspin.2021.105143_bib0520","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for COVID-19: living systematic review and network meta-analysis","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2021.105143_bib0525","article-title":"Update alert 2: hydroxychloroquine or chloroquine for the treatment or prophylaxis of COVID-19","author":"Hernandez","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2021.105143_bib0530","series-title":"Coronavirus (COVID-19) update: FDA revokes emergency use authorisation for chloroquine and hydroxychloroquine","author":"FDA.","year":"2020"},{"key":"10.1016\/j.jbspin.2021.105143_bib0535","first-page":"12","article-title":"A meta-analysis on the effects of hydroxychloroquine on COVID-19","author":"Hussain","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.jbspin.2021.105143_bib0540","first-page":"944","article-title":"Malaria chemotherapeutics part I: history of antimalarial drug development, currently used therapeutics, and drugs in clinical development","volume":"2","author":"Schlitzer","year":"2007","journal-title":"Med Chem"},{"key":"10.1016\/j.jbspin.2021.105143_bib0545","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofaa130","article-title":"Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)","volume":"7","author":"Pastick","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0550","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"Rainsford","year":"2015","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.jbspin.2021.105143_bib0555","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/14740338.2017.1269168","article-title":"Hydroxychloroquine in systemic lupus erythematosus (SLE)","volume":"16","author":"Ponticelli","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jbspin.2021.105143_bib0560","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0565","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","article-title":"2019 update of the Joint European league against rheumatism and European renal association\u2013European Dialysis and Transplant Association (EULAR\/ERA\u2013EDTA) recommendations for the management of lupus nephritis","author":"Fanouriakis","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0570","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.202012476","article-title":"Hydroxychloroquine in rheumatic autoimmune disorders and beyond","volume":"12","author":"Nirk","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.jbspin.2021.105143_bib0575","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","article-title":"Bioavailability of hydroxychloroquine tablets in healthy volunteers","volume":"27","author":"Tett","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0580","first-page":"1604","article-title":"Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome?","volume":"33","author":"Cunha","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jbspin.2021.105143_bib0585","series-title":"ACR meeting abstracts","first-page":"1844","article-title":"Hydroxychloroquine and QTc prolongation in a cohort of SLE patients","author":"Haj-Ali","year":"2020"},{"key":"10.1016\/j.jbspin.2021.105143_bib0590","doi-asserted-by":"crossref","first-page":"e000310","DOI":"10.1136\/lupus-2018-000310","article-title":"Changing paradigms in the treatment of systemic lupus erythematosus","volume":"6","author":"Fanouriakis","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jbspin.2021.105143_bib0595","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/art.41121","article-title":"Hydroxychloroquine blood levels predict hydroxychloroquine retinopathy","volume":"72","author":"Petri","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0600","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0605","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13075-020-02282-0","article-title":"Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicentre retrospective study","volume":"22","author":"Fernandez-Ruiz","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2021.105143_bib0610","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2019.07.010","article-title":"Management of cutaneous manifestations of lupus erythematosus: a systematic review","volume":"50","author":"Fairley","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105143_bib0615","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0620","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0961203319843343","article-title":"Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of pre-eclampsia","volume":"28","author":"Seo","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2021.105143_bib0625","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/1756-185X.13830","article-title":"Use of antimalarial drugs is associated with a lower risk of preeclampsia in lupus pregnancy: a prospective cohort study","volume":"23","author":"Saavedra M\u00c1","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0630","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2009.119263","article-title":"Evaluation of the risk of anti-SSA\/Ro-SSB\/La antibody-associated cardiac manifestations of neonatal lupus in foetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine","volume":"69","author":"Izmirly","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0635","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3899\/jrheum.150437","article-title":"Longitudinal evaluation of lipoprotein parameters in systemic lupus erythematosus reveals adverse changes with disease activity and prednisone and more favourable profiles with hydroxychloroquine therapy","volume":"43","author":"Durcan","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0640","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/1756-185X.13159","article-title":"Favourable effects of hydroxychloroquine on serum low density lipid in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"21","author":"Babary","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0645","doi-asserted-by":"crossref","first-page":"e15030","DOI":"10.1097\/MD.0000000000015030","article-title":"Impact of antimalarial (AM) on serum lipids in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis","volume":"98","author":"Tao","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.jbspin.2021.105143_bib0650","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3899\/jrheum.090994","article-title":"Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus NIH public access","volume":"37","author":"Kaprove Penn","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0655","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/rheumatology\/keu451","article-title":"Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study","volume":"54","author":"Chen","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105143_bib0660","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"Jung","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105143_bib0665","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3899\/jrheum.161351","article-title":"Long-term hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus","volume":"44","author":"Fasano","year":"2017","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0670","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1177\/0961203318811598","article-title":"Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort","volume":"27","author":"Gonz\u00e1lez-Echavarri","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2021.105143_bib0675","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/0961203319860579","article-title":"Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national Latin American lupus cohort","volume":"28","author":"Pimentel-Quiroz","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2021.105143_bib0680","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/1756-185X.13725","article-title":"Risk factors for herpes zoster infection among Filipinos with systemic lupus erythematosus","volume":"23","author":"Zamora","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0685","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/0961203319861685","article-title":"Causes and factors related to hospitalisations in patients with systemic lupus erythematosus: analysis of a 20-year period (1995\u20132015) from a single referral centre in Catalonia","volume":"28","author":"da Rosa","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2021.105143_bib0690","doi-asserted-by":"crossref","first-page":"8061","DOI":"10.12659\/MSM.919381","article-title":"Causes and factors associated with frequent hospitalisation in Chinese patients with systemic lupus erythematosus: an ambispective cohort study","volume":"25","author":"Liang","year":"2019","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.jbspin.2021.105143_bib0695","first-page":"1","article-title":"Patterns and predictors of recurrent acute care use among Medicaid beneficiaries with systemic lupus erythematosus","volume":"000","author":"Feldman","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105143_bib0700","first-page":"1","article-title":"Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","author":"Bruce","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0705","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/rheumatology\/kez584","article-title":"Risk factors of damage in early-diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort","volume":"59","author":"Piga","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2021.105143_bib0710","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1177\/0961203312445230","article-title":"Predictors of survival in Chinese patients with lupus nephritis","volume":"21","author":"Zheng","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2021.105143_bib0715","first-page":"0","article-title":"Hydroxychloroquine and mortality among patients with systemic lupus erythematosus in the general population","author":"Jorge","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2021.105143_bib0720","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0961203317739129","article-title":"Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort","volume":"27","author":"Mok","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2021.105143_bib0725","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmed.2020.00552","article-title":"Trend of survival of a cohort of Chinese patients with systemic lupus erythematosus over 25 years","volume":"7","author":"Mok","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.jbspin.2021.105143_bib0730","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1177\/0961203317726376","article-title":"Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis","volume":"27","author":"Pakchotanon","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2021.105143_bib0735","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1093\/rheumatology\/kez422","article-title":"Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission","volume":"59","author":"Zen","year":"2020","journal-title":"Rheumatology (United Kingdom)"},{"key":"10.1016\/j.jbspin.2021.105143_bib0740","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jbspin.2021.105143_bib0745","doi-asserted-by":"crossref","first-page":"e000395","DOI":"10.1136\/lupus-2020-000395","article-title":"Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus","volume":"7","author":"V\u00e1zquez-Otero","year":"2020","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jbspin.2021.105143_bib0750","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1002\/art.39194","article-title":"Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus","volume":"67","author":"Jallouli","year":"2015","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.jbspin.2021.105143_bib0755","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1136\/annrheumdis-2012-202322","article-title":"Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS study)","volume":"72","author":"Costedoat-Chalumeau","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0760","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjd.15312","article-title":"Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis","volume":"177","author":"Chasset","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0765","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","article-title":"Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in anti-phospholipid antibody-positive patients","volume":"13","author":"Petri","year":"2011","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jbspin.2021.105143_bib0770","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1160\/th15-06-0491","article-title":"The efficacy of hydroxychloroquine in altering pregnancy outcome in women with anti-phospholipid antibodies: evidence and clinical judgment","volume":"115","author":"Sciascia","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jbspin.2021.105143_bib0775","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0780","article-title":"Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome","author":"Nuri","year":"2016","journal-title":"Immunol Res"},{"key":"10.1016\/j.jbspin.2021.105143_bib0785","doi-asserted-by":"crossref","first-page":"102491","DOI":"10.1016\/j.autrev.2020.102491","article-title":"The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: a pilot open label randomised prospective study","volume":"19","author":"Kravvariti","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2021.105143_bib0790","doi-asserted-by":"crossref","first-page":"273e1","DOI":"10.1016\/j.ajog.2015.09.078","article-title":"The impact of hydroxychloroquine treatment on pregnancy outcome in women with anti-phospholipid antibodies","volume":"214","author":"Sciascia","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0795","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/rheumatology\/keq047","article-title":"Articular manifestations in primary Sj\u00f6gren's syndrome: clinical significance and prognosis of 188 patients","volume":"49","author":"Fauchais","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2021.105143_bib0800","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sj\u00f6gren syndrome: the JOQUER randomised clinical trial","volume":"312","author":"Gottenberg","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2021.105143_bib0805","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0810","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","article-title":"Hydroxychloroquine treatment for primary Sjogren's syndrome: a two-year double blind crossover trial","volume":"52","author":"Kruize","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0815","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.3346\/jkms.2016.31.7.1127","article-title":"Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sj\u00f6gren's syndrome: a double blind randomised control study","volume":"31","author":"Yoon","year":"2016","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jbspin.2021.105143_bib0820","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/1744666X.2019.1624527","article-title":"Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports rationale for combination therapy for Sj\u00f6gren's syndrome","volume":"15","author":"van der Heijden","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0825","series-title":"ACR meeting abstracts","article-title":"Clinical efficacy of leflunomide\/hydroxychloroquine combination therapy in patients with primary Sjogren's syndrome: results of a placebo-controlled double blind randomised clinical trial","author":"Radstake","year":"2018"},{"key":"10.1016\/j.jbspin.2021.105143_bib0830","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"van der Heijden","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0835","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1186\/s13063-020-04716-1","volume":"21","author":"Yang","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.jbspin.2021.105143_bib0840","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s10067-006-0218-1","article-title":"Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease","volume":"26","author":"Galva\u00f1","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0845","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2230.2004.01412.x","article-title":"Cutaneous hyperpigmentation during therapy with hydroxychloroquine","volume":"29","author":"Millard","year":"2004","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0850","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/jamadermatol.2018.2549","article-title":"Association between auto-antibody phenotype and cutaneous adverse reactions to hydroxychloroquine in dermatomyositis","volume":"154","author":"Wolstencroft","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0855","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1001\/archderm.141.7.855","article-title":"Combination antimalarials in the treatment of cutaneous dermatomyositis","volume":"141","author":"Ang","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0860","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/art.40064","volume":"69","author":"Aggarwal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0865","first-page":"12","article-title":"Lasting pathologic complete response to chemotherapy for ovarian cancer after receiving antimalarials for dermatomyositis","author":"Cadena","year":"2018","journal-title":"ECancer Med Sci"},{"key":"10.1016\/j.jbspin.2021.105143_bib0870","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0875","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/art.10228","article-title":"Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomised, double blind, placebo-controlled trial","volume":"46","author":"O\u2019Dell","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2021.105143_bib0880","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/S0140-6736(98)08513-4","article-title":"Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial","volume":"353","author":"M\u00f6tt\u00f6nen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2021.105143_bib0885","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(12)60027-0","article-title":"Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2-year follow-up of the randomised, non-blinded, parallel-group Swefot trial","volume":"379","author":"Van Vollenhoven","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2021.105143_bib0890","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.37765\/ajmc.2020.44075","article-title":"Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-na\u00efve patients","volume":"26","author":"Maksabedian Hernandez","year":"2020","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jbspin.2021.105143_bib0895","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00128071-200001030-00003","article-title":"Drug-induced psoriasis: recognition and management","volume":"1","author":"Tsankov","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0900","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0905","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/0002-9343(61)90213-3","article-title":"The treatment of sarcoidosis with chloroquine","volume":"30","author":"Morse","year":"1961","journal-title":"Am J Med"},{"key":"10.1016\/j.jbspin.2021.105143_bib0910","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0041-3879(67)80033-3","article-title":"Chloroquine in the treatment of sarcoidosis. A report from the research committee of the British tuberculosis association","volume":"48","author":"Davies","year":"1967","journal-title":"Tubercle"},{"key":"10.1016\/j.jbspin.2021.105143_bib0915","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1164\/ajrccm.160.1.9809024","article-title":"Randomised trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis","volume":"160","author":"Baltzan","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jbspin.2021.105143_bib0920","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1001\/archneur.55.9.1248","article-title":"Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement","volume":"55","author":"Sharma","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0925","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/1756-185X.13349","article-title":"Arthritis in sarcoidosis: a multicentric study from India","volume":"21","author":"Agarwal","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0930","first-page":"181","article-title":"Cutaneous sarcoidosis in Tunisia","volume":"143","author":"Khaled","year":"2008","journal-title":"Dermatol Venereol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0935","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/art.38956","article-title":"The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients","volume":"67","author":"Jachiet","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0940","first-page":"485","article-title":"Treatment of Horton disease. Value of synthetic antimalarials. A propos of a retrospective study of 36 patients","volume":"61","author":"Le Guennec","year":"1994","journal-title":"Rev Rhum Ed Fr"},{"key":"10.1016\/j.jbspin.2021.105143_bib0945","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10067-013-2245-z","article-title":"ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review","author":"Lenert","year":"2013","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0950","series-title":"ACR meeting abstracts","first-page":"1773","article-title":"New use for an old drug: hydroxychloroquine for the treatment of ANCA associated vasculitis","author":"Casian","year":"2017"},{"key":"10.1016\/j.jbspin.2021.105143_bib0955","series-title":"Talk: adding hydroxychloroquine to prednisone does not improve the outcome in giant cell arteritis. A double blind randomised controlled trial. ACR\/ARHP annual scientific meeting","first-page":"1972","author":"Sailler","year":"2009"},{"key":"10.1016\/j.jbspin.2021.105143_bib0960","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0965","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2021.105143_bib0970","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra062477","article-title":"Whipple's disease","volume":"356","author":"Fenollar","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2021.105143_bib0975","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1055\/s-0040-1710594","article-title":"Q fever (Coxiella Burnetii)","volume":"41","author":"Espa\u00f1a","year":"2020","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jbspin.2021.105143_bib0980","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1586\/14787210.2013.840534","article-title":"Antimicrobial therapies for Q fever","volume":"11","author":"Kersh","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jbspin.2021.105143_bib0985","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00280-016-3197-1","article-title":"Research progress of hydroxychloroquine and autophagy inhibitors on cancer","volume":"79","author":"Shi","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jbspin.2021.105143_bib0990","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2019-001014","article-title":"EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases","volume":"5","author":"Najm","year":"2019","journal-title":"RMD Open"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X21000154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X21000154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T16:27:24Z","timestamp":1761150444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X21000154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1297319X21000154"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2021.105143","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2021.105143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105143"}}